FDA EXTENDS PUBLIC COMMENT PERIOD ON OXITEC’S DRAFT ENVIRONMENTAL ASSESSMENT AND
PRELIMINARY FINDING OF NO SIGNIFICANT IMPACT
The US Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) announced today that they are extending the public review and comment period on the preliminary finding of no significant impact (FONSI) and Oxitec’s draft Environmental Assessment on Oxitec’s OX513A Aedes aegypti mosquito.
The original public review and comment period, which began on March 14, 2016, was for 30 days. The FDA has extended the comment period for 30 additional days and it will now conclude on May 13, 2016.
The publication of the FONSI and the EA follows an FDA-led evaluation of potential impacts of Oxitec’s proposed trial on public health and the environment. The team that performed the evaluation consisted of the FDA-CVM, the Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA).
The purpose of Oxitec’s proposed trial is to determine the efficacy of Oxitec’s OX513A mosquitoes as a control method of the Aedes aegypti mosquito.
The link to the EA and the FONSI are available on the homepage of the FKMCD website (http://www.keysmosquito.org). For more information, please contact the Florida Keys Mosquito Control District by email (email@example.com) or phone (305-292-7190).
About the Florida Keys Mosquito Control District
The mission of the Florida Keys Mosquito Control District is to control the mosquito population using the most effective methods, techniques, equipment and insecticides; thus enhancing the quality of life for all residents and reducing the possibility of mosquito transmitted diseases.
Follow FKMCD on Twitter at @FlKeysMosquito and on Facebook. For more information about the Florida Keys Mosquito Control District and to place a service request, please visit www.keysmosquito.org or call 305-292-7190.